HomeTG Therapeutics (TGTX) CEO Michael Weiss On Approaching Cancer Treatments
TG Therapeutics (TGTX) CEO Michael Weiss On Approaching Cancer Treatments

Michael Weiss explains TG Therapeutics cancer drugs with expected PDUFA dates. He says they have a multiple sclerosis drug with a target approval for mid-year 2022. He says their R&D expense has come down and they have $600 million in cash as of the end of the year.

ON AIR
2:30 pm
Fast Market
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Trading 360
REPLAY
4:00 am
Fast Market
REPLAY
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
education
9:30 am
Your First Trade
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
1:30 pm
Trading 360
REPLAY
ON AIR
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
education
4:30 pm
Your First Trade
REPLAY
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
education
8:00 pm
Your First Trade
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US